Servier’s Emi-Le Shows Promise in Rare ACC Cancer Trial
BOSTON, June 1, 2026 Servier has announced encouraging new clinical findings for Emiltatug Ledadotin (Emi-Le), an investigational B7-H4-targeted antibody-drug...
Servier
Advertisement
Servier’s VORANIGO® Delivers More Than 44 Months of Progression-Free Survival in IDH-Mutant Glioma
BOSTON, Massachusetts, May 31, 2026 Servier has announced extended follow-up results from the pivotal Phase 3 INDIGO trial, demonstrating...
Servier Advances OJEMDA Front-Line Brain Cancer Trial
BOSTON – May 8, 2026 Day One Biopharmaceuticals, now part of Servier Group, announced the completion of patient enrollment...
Advertisement
